Evidence map›Paper›PMID 39195242›Full record

ArticleCells2024

CMTM3 Suppresses Proliferation and Osteogenic Transdifferentiation of C2C12 Myoblasts through p53 Upregulation.

Enzhao Shen, Meiyu Piao, Yuankuan Li, Yuecheng Wu, Sihang Li, Sung Ho Lee, Litai Jin, Kwang Youl Lee

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Enzhao ShenCollege of Pharmacy, Research Institute of Pharmaceutical Sciences, Chonnam National University, Gwangju 61186, Republic of Korea.
Meiyu PiaoCollege of Pharmacy, Research Institute of Pharmaceutical Sciences, Chonnam National University, Gwangju 61186, Republic of Korea.ORCID 0009-0001-8191-4343
Yuankuan LiCollege of Pharmacy, Research Institute of Pharmaceutical Sciences, Chonnam National University, Gwangju 61186, Republic of Korea.ORCID 0009-0001-8034-7017
Yuecheng WuSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325000, China.
Sihang LiSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325000, China.
Sung Ho LeeCollege of Pharmacy, Research Institute of Pharmaceutical Sciences, Chonnam National University, Gwangju 61186, Republic of Korea.ORCID 0000-0002-4654-384X
Litai JinSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325000, China.
Kwang Youl LeeCollege of Pharmacy, Research Institute of Pharmaceutical Sciences, Chonnam National University, Gwangju 61186, Republic of Korea.

Funding

National Research Foundation of Korea 2019R1A5A2027521
6 · The paper itself

Abstract

CKLF-like MARVEL transmembrane domain-containing 3 (CMTM3), a member of the CMTM family that is closely related to tumor occurrence and progression, plays crucial roles in the immune system, cardiovascular system, and male reproductive system. Recently, CMTM3 has emerged as a potential target for treating diseases related to bone formation. However, additional studies are needed to understand the mechanisms by which CMTM3 regulates the process of osteogenic differentiation. In this study, we observed a significant downregulation of

Indexed as

Cell ProliferationCell TransdifferentiationChemokinesMARVEL Domain-Containing ProteinsMyoblastsOsteogenesisTumor Suppressor Protein p53AnimalsBone Morphogenetic Protein 4Cell LineHumansMiceOsteoblastsUp-RegulationBone Morphogenetic Protein 4ChemokinesCMTM3 protein, humanMARVEL Domain-Containing ProteinsTumor Suppressor Protein p53CMTM3myoblastosteoblastp53proliferationtransdifferentiation

Identifiers

PMID39195242
PMCPMC11352514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.